Fatal congestive heart failure with deferiproneAQODAD, N; LOREAL, O; ERDTMAN, L et al.Gastroentérologie clinique et biologique. 2008, Vol 32, Num 6-7, pp 656-657, issn 0399-8320, 2 p.Article

High doses of deferiprone may be associated with cerebellar syndromeBEAU-SALINAS, F; GUITTENY, M. A; DONADIEU, J et al.BMJ. British medical journal (International ed.). 2009, Vol 338, Num 7695, pp 653-653, issn 0959-8146, 1 p.Article

La chélation du fer en 1998 = Iron chelationDE MONTALEMBERT, M.Transfusion clinique et biologique (Paris). 1998, Vol 5, Num 5, pp 353-356, issn 1246-7820Article

Comparison of the effects of deferasirox, deferiprone, and deferoxamine on the growth and virulence of Vibrio vulnificusGANESH PRASAD NEUPANE; KIM, Dong-Min.Transfusion (Philadelphia, PA). 2009, Vol 49, Num 8, pp 1762-1769, issn 0041-1132, 8 p.Article

Purging iron from the heartHERSHKO, Chaim; CAPPELLINI, Maria D; GALANELLO, Renzo et al.British journal of haematology. 2004, Vol 125, Num 5, pp 545-551, issn 0007-1048, 7 p.Article

Emerging understanding of the advantage of small molecules such as hydroxypyridinones in the treatment of iron overloadHIDER, Robert C; LIU, Zu D.Current medicinal chemistry. 2003, Vol 10, Num 12, pp 1051-1064, issn 0929-8673, 14 p.Article

The Fenton Activity of Iron(III) in the Presence of DeferiproneDEVANUR, Lakshmi D; NEUBERT, Hendrik; HIDER, Robert C et al.Journal of pharmaceutical sciences. 2008, Vol 97, Num 4, pp 1454-1467, issn 0022-3549, 14 p.Article

Influence of the chelator 1,2-dimethyl-3-hydroxypyrid-4-one on aluminum elimination in aluminum-loaded rabbitsXI, C; PING, L; WUSHIDE et al.Trace elements and electrolytes. 1997, Vol 14, Num 3, pp 130-133, issn 0946-2104Article

Oral Iron chelation therapy with Deferiprone in patients with Thalassemia MajorSAJID, Raihan; GHANI, Farooq; ADIL, Salman et al.Journal of the Pakistan Medical Association. 2009, Vol 59, Num 6, pp 388-390, issn 0030-9982, 3 p.Article

Regression of Symptoms After Selective Iron Chelation Therapy in a Case of Neurodegeneration with Brain Iron AccumulationLUCA FOMI, Gian; BALOCCO, Manuela; CREMONESI, Laura et al.Movement disorders. 2008, Vol 23, Num 6, pp 905-908, issn 0885-3185, 4 p.Article

Timed non-transferrin bound iron determinations probe the origin of chelatable iron pools during deferiprone regimens and predict chelation responseAYDINOK, Yesim; EVANS, Patricia; MANZ, Chantal Y et al.Haematologica (Roma). 2012, Vol 97, Num 6, pp 835-841, issn 0390-6078, 7 p.Article

Daily alternating deferasirox and deferiprone therapy for hard-to-chelate β-thalassemia major patientsBALOCCO, Manuela; CARRARA, Paola; PINTO, Valeria et al.American journal of hematology. 2010, Vol 85, Num 6, pp 460-461, issn 0361-8609, 2 p.Article

Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemiaHENTER, Jan-Inge; KARLEN, Jonas.Blood. 2007, Vol 109, Num 12, pp 5157-5159, issn 0006-4971, 3 p.Article

Deferiprone iron chelation as a novel therapy for experimental mucormycosisIBRAHIM, Ashraf S; EDWARDS, John E; YUE FU et al.Journal of antimicrobial chemotherapy (Print). 2006, Vol 58, Num 5, pp 1070-1073, issn 0305-7453, 4 p.Article

Traitement de la surcharge en fer dans les maladies hématologiques (hémochromatoses héréditaires exclues) = Treatment of iron overload in hematological diseases (hereditary hemochromatosis excluded)GIROT, Robert; HAGEGE, Isabelle; DEUX, Jean-Francois et al.Hématologie (Montrouge). 2006, Vol 12, Num 3, pp 181-193, issn 1264-7527, 13 p.Article

Advances in iron overload therapies. Prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NAll and their combinationsKONTOGHIORGHES, George J; ERACLEOUS, Eleni; ECONOMIDES, Charalambos et al.Current medicinal chemistry. 2005, Vol 12, Num 23, pp 2663-2681, issn 0929-8673, 19 p.Article

Chelating agents used for plutonium and uranium removal in radiation emergency medicineFUKUDA, Satoshi.Current medicinal chemistry. 2005, Vol 12, Num 23, pp 2765-2770, issn 0929-8673, 6 p.Article

Chelators as antidotes of metal toxicity : Therapeutic and experimental aspectsBLANUSA, Maja; VARNAI, Veda M; PIASEK, Martina et al.Current medicinal chemistry. 2005, Vol 12, Num 23, pp 2771-2794, issn 0929-8673, 24 p.Article

Role of deferiprone in chelation therapy for transfusional iron overloadHOFFBRAND, A. Victor; COHEN, Alan; HERSHKO, Chaim et al.Blood. 2003, Vol 102, Num 1, pp 17-24, issn 0006-4971, 8 p.Article

Monitoring long-term efficacy of iron chelation therapy by deferiprone and desferrioxamine in patients with β-thalassaemia major: application of SQUID biomagnetic liver susceptometryFISCHER, Roland; LONGO, Filomena; NIELSEN, Peter et al.British journal of haematology. 2003, Vol 121, Num 6, pp 938-948, issn 0007-1048, 11 p.Article

Safety monitoring of cardiac and hepatic systems in β-thalassemia patients with chelating treatment in TaiwanPENG, Ching-Tien; CHOW, Kuan-Chih; CHEN, Jeon-Hor et al.European journal of haematology. 2003, Vol 70, Num 6, pp 392-397, issn 0902-4441, 6 p.Article

Labile plasma iron in iron overload: redox activity and susceptibility to chelationESPOSITO, Breno P; BREUER, William; SIRANKAPRACHA, Pornpan et al.Blood. 2003, Vol 102, Num 7, pp 2670-2677, issn 0006-4971, 8 p.Article

Iron chelator research: Past, present, and futureTAM, Tim F; LEUNG-TOUNG, Regis; LI, Wanren et al.Current medicinal chemistry. 2003, Vol 10, Num 12, pp 983-995, issn 0929-8673, 13 p.Article

The safety and effectiveness of deferiprone in a large-scale, 3-year study in Italian patientsCECI, Adriana; BAIARDI, Paola; SCHETTINI, Francesco et al.British journal of haematology. 2002, Vol 118, Num 1, pp 330-336, issn 0007-1048Article

Cellular zinc content is a major determinant of iron chelator-induced apoptosis of thymocytesMACLEAN, Kirsteen H; CLEVELAND, John L; PORTER, John B et al.Blood. 2001, Vol 98, Num 13, pp 3831-3839, issn 0006-4971Article